DEFOPHARMA
ActiveSummary
DEFOPHARMA has been active since 2019 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €67k and a net result of €19k. Equity is growing by ~39.1% per year across the filed fiscal years. Its solvency ranks better than 41% of 4604 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.4% (very low).
Checked score
Score 2024
Axes · tick = 2023
Profitability65▲+3
Solvency64▲+10
Growth78=
Track record100
Bankruptcy probability, 12 months
0.4%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €4k at 30 days acceptable
Liquidity tight (current ratio 1.16 against 0.9 in 2023; short-term debt: 21% and cash: 0.2% of total assets), and 61.3% of the assets are financed with debt.
Credit check for your own amount and term
Open the credit simulator : see how the verdict changes with amount, term and advance.
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 70
Relative position
BE, all sectors
reference
Activities of head offices; management consultancy activities (NACE 70)
about 69% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
38.7%
Return on assets
10.8%
Age of the figures
21 mo
neutral · Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 30-09-2025, 61 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 4 filingsDeviation from the deadline
2025
not confirmed
2024
61 d late
2023
77 d late
2021
44 d early
2020
27 d late
← before the deadline
after the deadline →
Checked, nothing found (1)
Financials · fiscal year 2024, full schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€19k▲ 15.8%
2023 · €16k
Working capital
€6k
2023 · €-4k
Trend over the years
Click a name to add, emphasise or remove a line.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line2020202120232024
Operating result€12k-€9k▼ 24.7%€16k-€23k▲ 47.0%
Net result€5k-€4k▼ 25.0%€16k-€19k▲ 15.8%
Equity€18k-€22k▲ 22.7%€48k-€67k▲ 38.8%
Total assets€147k-€136k▼ 7.5%€163k-€172k▲ 5.2%
Debt€129k-€114k▼ 11.7%€116k-€105k▼ 8.7%
Working capital€-21k-€-25k▼ 17.5%€-4k-€6k
Result per fiscal year
Operating resultNet result
The operating result rises in 2024; 2024 is 47% above 2023 and is the highest result in the available series.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €172k
Fixed assets
€130k =
Current assets
€42k ▲ 25.6%
Equity and liabilities €172k
Equity
€67k ▲ 38.8%
Debt
€105k ▼ 8.7%
Debt's share of the balance-sheet total falls from 70.7% to 61.3%. Equity is higher and debt is lower.
Key figures and ratios
Current ratio
1.16▲
2023 · 0.90
Debt to equity
1.58▼
2023 · 2.41
ROE
28.0%▼
2023 · 33.5%
ROA
10.8%▲
2023 · 9.8%
Debt ≤ 1 year
€36k▼
2023 · €37k
Debt > 1 year
€69k▼
2023 · €78k
Income taxes
€2k▲
2023 · €-2k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2020 | 2021 | 2023 | 2024 | Change |
|---|---|---|---|---|---|
| Gross operating margin9900 | €12k | €9k | €16k | €23k | ▲ 47.0% |
| Operating profit (loss)9901 | €12k | €9k | €16k | €23k | ▲ 47.0% |
| Financial charges65/66B | - | €3k | €2k | €2k | ▲ 35.6% |
| Recurring financial charges65 | €3k | €3k | €2k | €2k | ▲ 35.6% |
| Profit (loss) for the period before taxes9903 | €9k | €6k | €14k | €21k | ▲ 48.4% |
| Income taxes67/77 | €4k | €2k | €-2k | €2k | ▲ 203% |
| Profit (loss) for the period9904 | €5k | €4k | €16k | €19k | ▲ 15.8% |
| Profit (loss) for the period to be appropriated9905 | €5k | €4k | €16k | €19k | ▲ 15.8% |
| Line | 2020 | 2021 | 2023 | 2024 | Change |
|---|---|---|---|---|---|
| Assets | |||||
| Total assets20/58 | €147k | €136k | €163k | €172k | ▲ 5.2% |
| Fixed assets21/28 | €130k | €130k | €130k | €130k | = |
| Financial fixed assets28 | €130k | €130k | €130k | €130k | = |
| Current assets29/58 | €17k | €6k | €33k | €42k | ▲ 25.6% |
| Amounts receivable within one year40/41 | €17k | €5k | €33k | €42k | ▲ 24.9% |
| Trade receivables40 | - | €4k | €33k | €42k | ▲ 24.9% |
| Other amounts receivable41 | - | €1k | - | - | - |
| Cash at bank and in hand54/58 | €509 | €21 | €88 | €318 | ▲ 263% |
| Deferred charges and accrued income490/1 | - | €849 | - | - | - |
| Equity and liabilities | |||||
| Total equity and liabilities10/49 | €147k | €136k | €163k | €172k | ▲ 5.2% |
| Equity10/15 | €18k | €22k | €48k | €67k | ▲ 38.8% |
| Contributions10/11 | - | €12k | €12k | €12k | = |
| Profit (loss) carried forward14 | €5k | €9k | €36k | €54k | ▲ 52.3% |
| Amounts payable17/49 | €129k | €114k | €116k | €105k | ▼ 8.7% |
| Amounts payable after more than one year17 | €91k | €83k | €78k | €69k | ▼ 11.6% |
| Financial debts170/4 | - | €83k | €66k | €57k | ▼ 13.8% |
| Other amounts payable178/9 | - | - | €13k | €13k | = |
| Amounts payable within one year42/48 | €38k | €31k | €37k | €36k | ▼ 2.6% |
| Current portion of amounts payable after more than one year42 | - | €9k | €8k | €9k | ▲ 11.2% |
| Trade debts44 | €17k | €5k | €5k | €5k | ▲ 11.9% |
| Suppliers440/4 | - | €5k | €5k | €5k | ▲ 11.9% |
| Taxes, remuneration and social security45 | - | €13k | €24k | €22k | ▼ 10.0% |
| Taxes450/3 | - | €8k | €9k | €7k | ▼ 29.3% |
| Remuneration and social security454/9 | - | €5k | €15k | €15k | ▲ 2.1% |
| Other amounts payable47/48 | - | €5k | - | - | - |
| Accrued charges and deferred income492/3 | - | €864 | - | - | - |
| Line | 2020 | 2021 | 2023 | 2024 | Change |
|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €5k | €4k | €16k | €19k | ▲ 15.8% |
| Operating cash flow (approximation) | €5k | €4k | €16k | €19k | ▲ 15.8% |
| Investment in fixed assets (approximation) | - | €0 | - | €0 | - |
| Change in cash | - | €-489 | - | €230 | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
30-09
NBB filing
Annual accounts filed
fiscal year 2024 · full schema · 61 days late
2024
31-12
Financial
Highest result since 2020net €19k ▲15.8%
Operating result €23k, net result €19k, both a record.
16-10
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 77 days late
2022
17-06
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
31-12
Financial
Weakest financial yearnet €4k ▼25%
Net result drops to €4k, the lowest in the series; recovery starts the following year.
27-08
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema · 27 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 1 act read
About the unread acts
We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Lessines · 1 establishment unit since 2019
Ground area
1,454 m²
Building footprint
215 m²
Volume, LiDAR
1,727 m³
2 parcels, Brussels, Wallonia · tallest building 16.9 m, ±5 floors. Linked by address, not a title deed.
1 establishment unit
Defopharma
since 20192.392.021.087
2 parcels
Wallonia
1
(50%)
Brussels
1
(50%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 55023C0128/00V002 | Wallonia | 1,394 m² | 1 · 155 m² | 7.9 m · 2 fl. |
| 21009A0960/00N004 | Brussels | 59 m² | 1 · 60 m² | 16.9 m · 5 fl. |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
UNICLI Advisory Services
BE 0832.733.815
Tervuren · Eq €66,580
All Products For Industries
BE 0882.143.239
Knokke-Heist · Eq €66,578
Jolle
BE 0746.548.622
Tongeren-Borgloon · Eq €66,563
BOENK DEROB
BE 0775.714.641
Bilzen-Hoeselt · Eq €66,605
Beyens Projects
BE 0791.530.193
Kortenberg · Eq €66,559
Of 82,632 companies in sector 70200 we hold annual accounts for 52,575. 39,449 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded09-08-2019
Fiscal year end31-12
Activities, NACEBEL 2025
70200Business and other management consultancy
Contact
E-mail
pharmaciearnaudnicolas@gmail.com
Phone
+3225127598
Scores and ratios are computed by Checked and are not a credit decision.